This article on Epainassist.com has been reviewed by a medical professional, as well as checked for facts, to assure the readers the best possible accuracy.

We follow a strict editorial policy and we have a zero-tolerance policy regarding any level of plagiarism. Our articles are resourced from reputable online pages. This article may contains scientific references. The numbers in the parentheses (1, 2, 3) are clickable links to peer-reviewed scientific papers.

The feedback link “Was this Article Helpful” on this page can be used to report content that is not accurate, up-to-date or questionable in any manner.

This article does not provide medical advice.


The Role Of Microbiota In Cancer

  1. Introduction

    There are trillions and trillions of small microorganisms living in the human body. Groups of communities of these microorganisms are known as microbiota, and the entire collection of genes of all the microbes in a particular community is known as a microbiome. It may surprise many to know that these bacteria actually help keep us healthy and protect us from many diseases. The last few years have witnessed many great advances in microbiome research, with the emphasis being on the exact effect of the microbial populations that inhabit our gastrointestinal tract on our health and diseases in general. Keep reading to find out about the role of microbiota in diseases like cancer.

    1. Definition of Microbiota and Its Role In Human Health

      Microbiota is defined as the collection of living microorganisms that are located within a specified environment, such as the gastrointestinal tract or gut. When we talk about human microbiota, we usually refer to the trillions of microbes that live in the gut. The term microbiome is used to refer to the environment they live in. Most microbes in the body tend to be beneficial, though they may also become harmful and cause diseases when their numbers become imbalanced. While people tend to use the terms microbiota and microbiome interchangeably, it is not right since the microbiota refers to the huge variety of bacteria, fungi, viruses, and any other microorganisms that are present in a single environment, while the term microbiome refers to the larger, whole habitat of the human body. Microbiome includes all the microorganisms, genomes, and even the overall environmental conditions.(1,2)

      There is a symbiotic relationship between the human body and the microbes that live in it. This symbiotic relationship is beneficial to the microbes as well as the hosts, but only as long as the body remains in a healthy state of balance. It is estimated that there are nearly ten times more microbial cells present in the human body as compared to human cells. Some researchers, though, believe that this ratio is actually closer to 1:1.(3)

      In fact, it is even estimated that there might very well be over 1000 different species of microorganisms that make up the entire human microbiota. At the same time, it is important to note that the exact composition of the human biome tends to vary greatly from person to person. Different parts of the body also play host to different microbial communities and they impact your health in different ways.(4,5)

      When humans are born, the microbiome begins to develop and continues to change throughout their lifetime, depending on their lifestyle, genetics, age, gender, and many other factors. It is interesting to note that most of this microbiome is actually found in the gut. While every person’s microbiome is different, what factors exactly make up a healthy and thriving microbiome still remains a hotly debated topic that needs a lot of research even today. What researchers do agree upon, though, is that if this microbiome becomes imbalanced, then these changes can lead to a variety of diseases, including cancer. Research has pointed towards the fact that when these microbes get disturbed from their natural state and environment, which can be due to factors like the excessive use of antibiotics, changes in your diet, or even in cases of infections, this beneficial and symbiotic relationship can quickly turn negative.(6)

    2. Overview of the Relationship Between Microbiota and Cancer

      As mentioned above, there is a growing body of research that has established that the microbiota in our bodies have an important role to play in not only the development, but also the progression of various types of cancer. There are many reasons behind why this happens.(7)

      The first factor is that the microbiota is directly responsible for boosting the development of cancer in two ways – one is by producing carcinogenic metabolites or the second is by causing chronic inflammation. For example, when the microbiota of Helicobacter pylori, which is a bacteria that thrives in the stomach, gets imbalanced, it is known to lead to the development of gastric cancer.(8,9)

      Another factor behind why microbiota is believed to be responsible for altering the immune system, while also impacting the immune system‘s response to cancer treatment. Many studies have shown that there are certain types of bacteria in the body that boosts the efficacy of cancer treatments like immunotherapy, while there are many others that can also disrupt it.(10,11,12)

      The last factor is that the microbiota can also affect the development of cancer and its progression. This happens because of the effect human microbiota has on the gut-brain axis, which refers to the communication channel that exists between our gut and the central nervous system. This gut-brain axis is believed to play an important role in the progression of cancer as it has an impact on inflammation, immune response, and stress.(13,14)

      There is no doubt that there is a clear relationship between microbiota in the body and the development and progression of cancer, even though this relationship is multi-dimensional and quite complex to understand. Research is still going on to better understand this relationship and it is expected that the more we find out about this, the better are the chances to develop new strategies for cancer treatment, and perhaps even cancer prevention.

    3. Purpose and Significance of the Article

      An article on the role of microbiota in cancer can be significant for many reasons. One of the major purposes is to educate and inform the general public, healthcare professionals, and even researchers about the growing body of evidence that hints at the association between the human microbiota and cancer development and progression. Such an article can help promote awareness about the importance of maintaining a healthy microbiota as well as the potential for microbiota-based interventions in cancer prevention and treatment. This can also lead to a much better understanding, diagnosis, and treatment of various types of cancers.

      Such an article also provides a comprehensive overview of the current state of research on this topic. This can help researchers to identify gaps in knowledge and to guide future research directions. In addition, this article can prove to be helpful in the development of new cancer therapies. Researchers and pharmaceutical companies can leverage such kind of information to develop new drugs and therapies that target the microbiota, which could potentially boost the efficacy of current cancer treatments or develop new treatments altogether.

      There is no doubt that an article such as this, on the role of microbiota in cancer, can prove to be a valuable resource for all the stakeholders, including patients, healthcare professionals, researchers, and even policymakers.

  2. Microbiota and Cancer

    1. Discussion of the Impact Of Microbiota On Cancer Development And Progression

      As mentioned above, there is a growing body of evidence that shows that there is a definite link between the microbiota in our bodies and the development and progression of various types of cancer. In fact, even though this exact relationship between the microbiota and cancer is complex and is believed to be multi-layered, there are many ways in which the microbiota impacts the development and progression of cancer in the body.

      Several recent studies have indicated that any change in the gut microbiota can enhance carcinogenesis in the body by increasing the hyperproliferation of colon cells. During the process of colonization and propagation, bacteria present in the gut begin producing a variety of metabolites that are known to have both direct as well as indirect influences on your immune response and metabolism processes.(15,16) Evidence has shown that disturbance to the gut microbiota can actually boost the production of carcinogenic products. Gut microbiota and the metabolites that they produce can also cause epigenetic modifications in other cells of the body, meaning that they change the genetic information.(17)

      Furthermore, any change in the composition of the gut microbiota is also known to cause chronic inflammation. The disruption of gut microbiota, a process known as gut dysbiosis, can be influenced by your genes, diet, intake of antibiotics, and many other factors. Gut dysbiosis can increase the presence of inflammatory cytokine-producing immune cells, which enhances inflammation in the body and is considered to be the ideal stimulant for the development of tumors.(18,19,20)

      The bacteria that remain prominent during the process of gut dysbiosis are actually capable of secreting certain types of toxins that interfere with your cell growth, which again predisposes you to the development of cancer.

      The microbiota is also known to have an effect on the immune response of the body to cancer. There are certain types of bacteria that are able to stimulate an immune response in the body that helps the body fight the cancer cells, but on the other hand, there are also some harmful bacteria that can suppress the immune system, which allows the cancer cells to rapidly grow and spread.

      Then there is also the role of the gut-brain axis to take into consideration. The bacteria present in our gut cooperate with other systems to regulate the development and boost the functioning of the immune, nervous, and metabolic systems in the body. This dynamic communication is often termed as the gut-brain axis. This communication channel also plays a major role in controlling stress, immune response, and even inflammation in the body. Since the microbiota has an impact on the gut-brain axis, directly or indirectly it affects the development and progression of cancer.(21)

      As can be seen from all this, the microbiota has a significant impact on cancer development and progression. However, more research is still needed to completely understand how this mechanism works.(22)

    2. Analysis of the Potential Mechanisms of Action, Including Inflammation, Immune System Modulation, and Metabolic Changes

      We have already mentioned that the exact role of the microbiota in the body is quite complex and there are many facets to it, involving a combination of many mechanisms. The role of microbiota in the development and spread of cancer has been an active field of research for many years now, and many mechanisms of action have since been proposed by experts.

      The gut microbiota in humans has been implicated in the development of cancer and at the same time, it has been found to impact anti-cancer drug efficacy. An imbalance in gut microbiota is linked with resistance to chemotherapy drugs or to immune checkpoint inhibitors, or ICIs, while some other bacterial species also help restore or enhance the immune response to anti-cancer drugs. Due to this, a growing body of evidence has revealed that changing the gut microbiota can help boost the efficiency of cancer treatments.(23)

      When it comes to inflammation, chronic inflammation in the body has been associated with the development and spread of many types of cancer. It is believed that gut microbiota can efficiently alter the immune response of the body including inflammation in the gut, thus lowering the risk of cancer. Studies have shown that there are certain strains of bacteria present in the gut that can produce metabolites, which are substances formed in or required for metabolism. These metabolites can activate the immune cells and increase inflammation, thus increasing the risk of colon cancer in people.(24,25)

      The modulation of the immune system also has a role to play. For example, there are certain strains of gut bacteria that are known to boost the development of regulatory T cells in the body, which are known to have a protective effect against many types of cancer. The gut microbiota interacts with the immune system to promote the development of these regulatory T cells, which are also helpful in relieving inflammation and also maintaining immune tolerance.(26)

      Metabolic changes also have a potential role to play in all this. This is because the gut microbiota also has an impact on human metabolism. This has an eventual influence on the risk of cancer. For instance, there are certain strains of gut bacteria that are capable of breaking down some dietary components into metabolites. These then get absorbed and used by other cells in the body. The metabolites can have a wide range of effects on the body, including:(27)

      • Regulation of gene expression
      • Modulation of the cellular signaling pathways

      As mentioned earlier, some of these metabolites have anti-cancer properties and actually enhance the workings of cancer treatment, while others actually increase the risk of developing cancer.

      Some studies have also shown that the gut microbiota is able to interact directly with cancerous cells. In fact, some strains of bacteria have been found that promote the development and survival of cancerous cells even in vitro, while at the same time, others have anti-cancer properties.(28) Again, the underlying mechanisms of these impacts are not clearly understood, but they are also believed to include the production of metabolites by different bacterial strains. To develop any kind of strategy to prevent or treat cancer, more studies are necessary to get a clear understanding of these interactions and mechanisms between microbiota and cancer.(29)

    3. Overview of the Differences In Microbiota Composition Between Cancer Patients And Healthy Individuals

      The basic composition of the microbiome in every person is different. The differences in the human microbiome continue to change throughout their lifetime and depend on many factors that have been discussed above, including genetics, lifestyle, age, gender, etc. Since research on the microbiome and the development of cancer are still in their early stages, most of what is known about this field are derived from studies carried out on mice. For example, studies have been successful in showing that the composition of the gut microbiome has a direct impact on the size and number of tumors in mice who have liver cancer.(30)

      Other studies have also found differences in the makeup of the microbiota between cancer patients and people without cancer. For example, some research has shown that having a more diverse microbiome can actually help improve the efficiency of immunotherapy treatments used in many types of cancer, like skin cancer.(31) Other studies have also found that patients who have a more diverse microbiome in their guts are more likely to be alive for at least three years after undergoing a stem cell or bone marrow transplant.(32)

      While increased diversity helps improve the effectiveness of cancer treatments, on the other hand, some studies have also shown that patients with some types of cancer, like pancreatic and colorectal cancer, have a decreased gut microbiota.(33,34)

      There have also been some studies that found differences in the amount of certain bacterial strains present in cancer patients versus those of healthy individuals. For instance, a study carried out in 2012 by the Broad Institute of Massachusetts Institute of Technology and Harvard in the US discovered that the exact amount of the bacterial strain known as Fusobacterium nucleatum was dramatically higher in the tumor tissues of cancer patients as compared to the normal, healthy tissues that were just adjacent to these tumor tissues.(35)

      Yet another study discovered that the amount of some types of bacterial strains in the gut, including bacteria known as Faecalibacterium prausnitzii and Bacteroides fragilis, was significantly lower in patients of colorectal cancer as compared to healthy individuals.(36)

      Many other studies have also reached similar conclusions when looking at other types of cancer, such as pancreatic cancer and lung cancer. For example, a study done at the New York University School of Medicine in 2018 on patients with pancreatic cancer discovered that there was an abundance of a certain type of bacteria in the tumor tissues when compared to the nearby healthy tissues. The strains were abundantly higher of bacteria like Veillonella spp. and Streptococcus mitis.(37) Another similar research done in 2016 by the Seoul National University College of Medicine found that patients who had lung cancer had reduced levels of the strain Veillonella and Streptococcus as compared to healthy individuals.(38)

      There are also many clinical trials going on to learn more about how the differences in a healthy person’s microbiome can affect certain types of cancer and cancer treatments.

      Again, as mentioned, research on this field is still in its early phases due to which these studies are also majorly observational in nature and it is not completely clear whether these differences that have been observed in the composition of the microbiome are actually contributing to the development and progression of cancer or whether they are only a side effect of the illness itself. Nevertheless, this research is promising and highlights the potential of building new treatments focusing on the relationship between the microbiome and cancer.

  3. Microbiota and Cancer Treatment

    1. Analysis of the Impact Of Microbiota On Cancer Treatment Outcomes

      With so much of research being done on human microbiota, the association of microbiota playing a role in the outcome of cancer treatments has more or less been established firmly. Studies have already shown that the human microbiota is a key role in the overall maintenance of our health. It has a great influence on not only the gastrointestinal tract, but also the major organs like the liver, pancreas, and brain. Due to this, when there is an imbalance that occurs in this microbiota, it contributes to the development and progression of many diseases, including cancer. This is why it is not surprising that the microbiota also has a substantial impact on the outcomes of cancer treatments.

      Studies have shown that the makeup and functioning of the microbiota can not only influence the efficiency, but also the toxicity levels of many cancer therapies, including radiation therapy, immunotherapy, and chemotherapy. A recent study carried out in August 2022 by researchers from the Institute of Public Health, College of Medicine and Health Sciences in the United Arab Emirates explored the role that microbiota plays in determining the outcome of immunotherapy in colorectal cancer patients. The study compared the response of patients with colorectal cancer to immunotherapy to the exact composition of their gut microbiota.(39,40)

      Another study carried out on people with metastatic melanoma by the Baylor Scott & White Medical Center in 2018 and published in the Science Journal found that patients who have a more diverse gut microbiota, tend to respond better to cancer treatments like immunotherapy as compared to those patients who have lower diversity in their gut microbiota.(41) The patients who responded better to the immunotherapy for melanoma were those who had significantly higher levels of bacterial strains like Clostridiales and Faecalibacterium as compared to the patients who did not respond too well to the treatment. It was determined that these bacterial strains have an important role to play in boosting the immune system and also increasing the efficiency of immunotherapy in metastatic melanoma. The study also found that patients who had reduced quantities of these bacteria strains were found to have higher amounts of other types of bacteria, including bacteroidales that are known to restrict the immune system’s response to cancer treatments like immunotherapy. Bacteroidales are a group of bacteria that are typically present in the gut and are able to colonize it through specialized interactions with the host’s immune system and other metabolic processes.(42)

      Research has further indicated that patients who have a more diverse gut microbiome tend to respond better to cancer treatments like immunotherapy as compared to those patients who have a homogeneous microbiota.(43) It is believed that the microbiota is able to impact the outcomes of cancer treatments by changing or modulating the immune system. There are some bacterial strains that are known to boost or stimulate the immune system and cause them to attack the cancerous cells. On the other hand, there are other strains that work to suppress the body’s immune response, thus promoting the growth of cancerous tumors. This is why the exact composition of the microbiota can help doctors determine whether a patient will respond positively to immunotherapy or not.(44)

      The gut microbiota is also known to impact the outcome of cancer treatments as it metabolizes the cancer drugs. There are some types of bacteria that break down the chemotherapy drugs from the body, which reduces their efficiency. Similarly, there are other bacterial strains that help transform the inactive drugs into their active form, thus boosting their efficiency. At the same time, the gut microbiome can also impact the distribution and absorption of medications in the body, which affects their side effects and overall toxicity.(45)

      There is further proof to show that the gut microbiome, being very complex in its exact composition, can impact how the body responds to radiation therapy. There are some bacteria strains that protect tumors from the effects of radiation, while other bacterial strains actually make the tumors sensitive to radiation, thus making the treatment more effective.(46,47)

      All this research has shown a promise that by handling or manipulating the human microbiota, it might be possible to develop successful treatment strategies for cancer.

    2. Discussion of the Potential Mechanisms Of Action, Including Chemotherapy Resistance And Modulation Of The Immune System

      As discussed earlier, human microbiota has a big role to play in the success or failure of cancer treatment. There are several mechanisms through which the microbiota can enhance the efficiency of chemotherapy in many types of cancer. One such mechanism is by the alteration of the metabolic capabilities of the gut microbiota. When we refer to the metabolic capabilities of the gut microbiota, it means we are referring to the many biochemical processes that these microorganisms in the gut carry out for metabolizing nutrients and other substances that do not get easily digested by the human body. Some of these metabolic processes may include respiration, fermentation, and processes to manufacture compounds like vitamins, neurotransmitters, and even short-chain fatty acids. All of these processes have an effect on our overall well-being and the functioning of the body.(48,49)

      Similarly, the gut microbiota is capable of metabolizing the chemotherapy drugs, which impacts the processes of drug absorption, drug distribution, and drug toxicity as well. Due to this the presence of certain types of bacteria strains in the gut can enhance the efficiency of chemotherapy as the microbiota metabolizes the drugs in such a manner that their effectiveness and potency are improved significantly.(50)

      Another way mechanism through which human microbiota can help improve the efficacy of chemotherapy is by the alternation of the immune system. There are certain types of bacteria strains present in the gut microbiota that are known to boost the immune response to cancerous cells. For example, there are bacterial strains like Lactobacillus, Akkermansia muciniphila, and Bifidobacterium that are linked with an enhanced response of the immune system to chemotherapy.(51,52) These bacterial strains are known to manufacture certain types of metabolites that boost the immune system and also serve other purposes, such as lowering inflammation and improving the efficacy of chemotherapy. The bacterial strain Akkermansia muciniphila, in particular, has been found to play a major role in transforming the immune response to cancer and improving the efficacy of chemotherapy in animal models. However, human studies are still pending, though the results of animal studies appear to be quite promising.(53) This mechanism can lead to a higher death rate of the tumor cells and therefore, a better response of the patient to chemotherapy.

      The gut microbiota also has an influence on the overall well-being and health of cancer patients, which also has an indirect effect on the effectiveness of chemotherapy. For instance, since the gut microbiota helps regulate inflammation, it can help impact the progression of cancer and the overall response to chemotherapy. There are several bacterial strains that reduce inflammation, including Bifidobacterium, Lactobacillus, Akkermansia mucinphila, Faecalibacterium prausnitzii, and Roseburia.(54,55)

      While there is a lack of human studies, but it is safe to say that if cancer patients make an effort to improve the diversity and health of their gut microbiota by increasing their intake of prebiotics and probiotics, and also make other beneficial dietary changes, they can help improve their cancer outcome and also boost the efficiency of their cancer treatment.(56,57)

      While research has shown positive outcomes, there is also a drawback of the microbiota as it is known to sometimes cause chemotherapy resistance as well. Chemotherapy resistance refers to a phenomenon in which cancer cells become resistant to the effects of chemotherapy drugs, leading to treatment failure.

      There have been some studies that have found that some bacterial strains can eventually reduce the efficiency of the chemotherapy drugs, leading to chemotherapy resistance. In some cases, it may happen that some of the bacteria types cause the inactivation of the chemotherapy drugs or the bacteria start competing with the tumor cells to get to the nutrients, which lowers the amount of drug that is available in the body to actually attack and kill the cancerous tumor cells.(58,59)

      On the other hand, some types of chemotherapy drugs also cause certain changes in the composition and diversity of the microbiota in the body. These changes in the microbiota population can promote the growth of bacterial strains that are associated with inflammation and chemotherapy resistance.(60)

      However, more research is still needed to better understand the exact bacterial strains that could be involved in building chemotherapy resistance and to then develop better treatment strategies to overcome this resistance.

      Again, using probiotics, prebiotics, or other interventions to bring about a change in the gut microbiota can help improve the effectiveness of chemotherapy.

    3. Overview of the Use Of Microbiota-Based Interventions In Cancer Treatment, Including Fecal Microbiota Transplantation And Probiotics

      New research on using microbiota-based interventions in cancer treatment has been showing much promise.

      It has been found that many types of microbiota-based interventions can help boost the efficiency of chemotherapy, reduce the cases of chemotherapy-related toxicity, and even help overcome chemotherapy resistance in certain cases. One such example has been the success of using fecal microbiota transplantation (FMT) to improve the response of patients with advanced melanoma and non-small cell lung cancer to checkpoint inhibitor therapy.

      While there is limited data available as of now, but the limited research on the use of fecal microbiota transplantation, or FMT, has shown that it is successful in the treatment of cancer. There have been some pre-clinical studies and case studies that suggest that FMT can have a positive impact on cancer outcomes. In one case study, a patient with stage IV colon cancer who received FMT from a healthy donor had a positive response to immunotherapy and showed no signs of cancer even after one year of follow-up.(61) Another pre-clinical study discovered that when FMT is combined with chemotherapy, it helps improve the anti-tumor immune response, while also increasing the chances of survival in mice with colon cancer.(62)

      A recent study published in the Cancer Discovery Journal in 2021 had looked at the gut microbiota of cancer patients who were undergoing immunotherapy. The study found that the patients who had a more diverse and healthier gut microbiota experienced better responses to treatment and also had better overall survival chances. The researchers suggested that using microbiota-based interventions such as FMT could help restore a patient’s gut microbiota in order to potentially improve the outcomes of immunotherapy in cancer patients.(63)

      There is also a lot of interest in the use of prebiotics and probiotics for microbiota-based interventions in cancer. Prebiotics contain non-digestible dietary fibers that selectively boost the growth and activity of beneficial gut microbiota. Prebiotics have been found to improve the response to chemotherapy in cancer patients and also reduce the cases of chemotherapy-induced toxicity in animal studies.(64)

  4. Implications for Cancer Prevention

    1. Discussion of the Potential Of Microbiota-Based Interventions For Cancer Prevention

      There is a lot of emerging evidence that is promising in this regard. This evidence suggests that microbiota-based interventions can actually be used for cancer prevention. Studies have shown that the exact composition and diversity of gut microbiota can have a substantial impact on the development and progression of cancer. At the same time, interventions that can also modify the microbiota can actually help prevent cancer or even reduce the risk of cancer.

      Apart from regularly using prebiotics and probiotics, making certain positive dietary changes and lifestyle modifications can also promote a healthy microbiota, which has been found to lower the risk of cancer. For example, following a diet that is high in fiber, fruits, and vegetables has been linked with a decreased risk of developing many types of cancers, including colorectal cancer. (65) At the same time, indulging in regular physical activity has also been shown to promote healthy microbiota and reduce the risk of cancer.(66)

      While more research is needed in this area, there is a lot of promising evidence to indicate that microbiota-based interventions can be used successfully for cancer prevention.

    2. Analysis of the Evidence Supporting The Use Of Probiotics And Prebiotics For Cancer Prevention

      Prebiotics and probiotics have been shown to have anti-cancer properties and can reduce the risk of developing certain types of cancer. Prebiotics, which are non-digestible food ingredients that promote the growth of beneficial gut bacteria, have been found to decrease the risk of colorectal cancer.(67)

      Some prebiotics that have been found to play a potential role in cancer prevention is as follows:

      • Inulin: This prebiotic is a type of dietary fiber that can be found in many fruits, vegetables, and whole grains. Animal studies have shown that it has potential anti-cancer effects.(68,69)
      • Fructo-oligosaccharides (FOS): FOS is a type of prebiotic found in many fruits and vegetables, including bananas, onions, and garlic. Fructo-oligosaccharides have been found to have potential anti-cancer effects in animal studies.(70)
      • Galacto-oligosaccharides (GOS): This is a type of prebiotic found in human milk, as well as certain legumes and whole grains. It has been shown to have powerful anti-cancer effects in animal studies.(71)

      Probiotics, on the other hand, are live bacteria that provide a variety of health benefits to the host when consumed in limited amounts. Studies have found that there are certain probiotic strains that can alter the gut microbiota and reduce the risk of colon cancer.(72)

      Some probiotics that have been found to help in cancer prevention is as follows:

      • Lactobacillus acidophilus: Lactobacillus acidophilus is a type of probiotic that can be found in many fermented foods, including yogurt, kefir, and sauerkraut. Animal studies have found that this probiotic has powerful anti-cancer effects.(73)
      • Bifidobacterium bifidum: Another type of probiotic, Bifidobacterium bifidum can be found in many fermented foods and some dairy products. Studies have found that it has potential anti-cancer effects.(74)
      • Saccharomyces boulardii: This is a type of yeast probiotic that has been shown to have some powerful anti-cancer properties.(75)
    3. Overview of the Challenges And Limitations Of Microbiota-Based Interventions For Cancer Prevention

      While the field of microbiota-based interventions for cancer has been showing promise, it is still quite early to understand exactly how beneficial these therapies can be. Nevertheless, there are several challenges and limitations when we talk about microbiota-based interventions for cancer prevention. These include:

      • Diversity of the Microbiota: The microbiota of every person is unique, and there is a lot of variation in the composition and quantity of bacterial strains that are found between individuals. These differences in the microbiota have made it quite challenging to develop one ‘universal’ approach to such types of microbiota-based interventions that will work with every person.
      • Lack of Knowledge About How Microorganisms Function: While researchers have identified several microbial strains that are specifically associated with cancer, the exact manner in which these microorganisms promote or restrict the development and spread of cancer cells is not completely understood. This lack of understanding is a big challenge to the development of more effective microbiota-based interventions.
      • Limited Clinical Trials And Human Studies: While there is a growing body of evidence to suggest that the human microbiota plays an important role in cancer development and progression, there are presently very few clinical trials or human studies that are investigating whether microbiota-based interventions can play a role in cancer prevention. There is a pressing need for conducting larger and well-designed studies that can establish the effectiveness of such treatment and prevention methods
      • Safety Issues: There are, of course, concerns related to the safety of microbiota-based interventions, especially processes like fecal microbiota transplantation (FMT). These processes come with a risk of infections and there is also a potential for negative immune reactions and other side effects.
      • Lack of Standards: There is a lack of standardization in microbiota-based interventions. There are no standards in place for sourcing of microbiota, methods used for delivery, or the exact duration of treatment. Standardization of such factors is necessary to ensure there are no adverse reactions.
  5. Future Directions

    1. Discussion of Current Research and Future Directions In The Field Of Microbiota And Cancer

      Current research in the field of microbiota and cancer is more or less focused on increasing the understanding of the mechanisms by which gut microbiota affect the development and progression of cancer, while also focusing on the development of microbiota-based interventions for cancer prevention and treatment.

      Researchers have been studying the exact mechanisms by which the gut microbiota has an impact on cancer development and progression. For example, studies have been looking at how the metabolites produced by microbiota influence the growth and survival of cancer cells, and how gut bacteria can regulate immune responses to impact cancer development and spread.(76)

      Researchers are also trying to develop and test various microbiota-based interventions for cancer prevention and treatment. For instance, one study has been testing the effectiveness of probiotics, prebiotics, and FMT in decreasing the risk of cancer or at least to improve cancer outcomes.(77)

      There is also a growing interest in exploring the potential of using gut microbiota to regulate response of the patient to cancer treatments like immunotherapy. Researchers have been looking at how certain strains of gut bacteria can impact the effectiveness of immune checkpoint inhibitors, which is a type of cancer immunotherapy that targets certain molecules located on immune cells in order to boost their anti-cancer activity.(33)

      Furthermore, some studies have even suggested that the composition and function of microbiota could be used as biomarkers to better the process of cancer diagnosis and prognosis. Studies are looking at the capability of microbiota-based diagnostics to either complement or eventually replace the current traditional cancer screening methods.(78)

      In the coming years, research in the field of microbiota and cancer is expected to continue to focus on developing microbiota-based interventions for cancer prevention and treatment, while also looking at improving the basic understanding of the mechanisms by which gut microbiota impacts cancer.

    2. Analysis of the Potential Of Microbiota-Based Interventions For Personalized Cancer Treatment And Prevention

      With the growing interest in microbiota-based interventions, researchers have been looking at the potential of developing personalized approaches for cancer treatment and prevention. Personalized approaches to microbiota-based interventions take into account the individual differences in microbiota composition and function. For example, several studies are investigating how the use of specific probiotic strains or prebiotics can be customized or personalized to an individual’s unique microbiota profile to achieve the best cancer prevention or treatment outcomes.(79)

    3. Overview of the Challenges and Opportunities In The Development Of Microbiota-Based Interventions For Cancer

      Microbiota-based interventions have shown many promising results in both pre-clinical and animal/human studies for cancer prevention and treatment. However, there are still some challenges and opportunities associated that will develop and clear up only with time.

      Some of these challenges include:

      • Diversity of the Microbiota: As mentioned above, the human microbiota is highly diverse and varies from person to person, making it difficult to establish any kind of universal intervention strategies.
      • Safety Concerns: Microbiota-based interventions still carry many safety concerns including the risk of transferring infectious microorganisms or antibiotic resistance genes to the patient.
      • Regulatory Issues: Regulatory agencies have not yet come up with any clear guidelines for the development and approval of microbiota-based interventions.

      Some opportunities that exist in this field in the coming years include:

      • Personalized Medicine: As discussed in the earlier section, microbiota-based interventions is being explored as an option to personalize the treatments according to an individual’s microbiota composition.
      • Combination Therapies: There are opportunities of combining microbiota-based interventions with other therapies such as chemotherapy and immunotherapy, to improve the effectiveness of cancer treatments and also reduce toxicity.
      • Use of Probiotics and Prebiotics: Probiotics and prebiotics have shown a lot of promise in regulating the microbiota and lowering the risk of cancer. This can be a potential opportunity to explore in the future.
  6. Ethical and Social Considerations

    1. Discussion of Ethical and Social Considerations Related to the Use of Microbiota-Based Interventions For Cancer

      There is no doubt that the growing use of microbiota-based interventions for cancer has raised many ethical and social considerations that must be considered before the field develops more.

      The first issue that comes up is that of the patient’s informed consent. Patients need to be fully informed about the potential risks and benefits of microbiota-based interventions and provide their consent before undergoing such treatments.

      There are also concerns related to equity and access. After all, microbiota-based interventions are expensive and not available to all patients, which could aggravate any existing health disparities.

      There is also the issue of unintended consequences. Since not much is clearly understood about the human microbiota, changing the microbiota could have potentially unintended and adverse effects on other aspects of a patient’s health. There is a need for well-designed and long-term studies to fully understand the potential risks and benefits of such interventions.

    2. Analysis of the Potential Impact Of These Considerations On Access To Microbiota-Based Interventions And Outcomes

      The ethical and social considerations associated with the use of microbiota-based interventions for cancer can have a substantial impact on access to these interventions and their outcomes. Some of these impacts may include:

      • Who Gets The Treatment?: As mentioned above, there are several disparities when it comes to accessing microbiota-based interventions. These disparities are based on socioeconomic status, race, and even geography. Such factors could result in some people being denied potentially life-saving treatments.
      • Regulatory Challenges: The development and approval of microbiota-based interventions may face regulatory challenges due to the novelty and complexity of these interventions.
      • Privacy of Data: Microbiota-based interventions may involve collecting and analyzing sensitive health information from patients. This is why it is important to ensure that such information is kept safe to maintain patient privacy and prevent any type of patient discrimination.

      Addressing these considerations will be necessary to ensure that everyone gets access to potentially life-saving microbiota-based interventions.

    3. Strategies for Addressing Ethical and Social Considerations

      There are many strategies that can be put in place to address the ethical and social considerations related to the use of microbiota-based interventions for cancer. Some of these include:

      • Community Engagement: Community engagement can be an important strategy for ensuring that the development of microbiota-based interventions takes into account the needs and concerns of the communities that will be affected. This can involve engaging with patient advocacy groups, community leaders, and other stakeholders to ensure that their perspectives are heard and considered.
      • Promoting Education and Outreach: Education and outreach efforts can help raise awareness about the potential benefits and risks of microbiota-based interventions and can help address concerns and misconceptions that patients and the general public may have.
      • Ensuring Access for All: Ensuring equitable access to microbiota-based interventions is an important consideration, particularly given the potential for these interventions to be expensive or difficult to access. Efforts to ensure equitable access may include reducing costs, increasing insurance coverage, or developing programs to help low-income patients access these treatments.
      • Ethical and Regulatory Oversight: Finally, ensuring ethical and regulatory oversight of research and clinical use of microbiota-based interventions is critical. This may involve establishing ethical guidelines and review boards to ensure that the development and use of these interventions is consistent with ethical principles and that patients are protected from harm.
  7. Conclusion

  1. Summary of Key Findings

    While it is not easy to summarize the many possibilities that the field of microbiota-based interventions hold for the treatment and prevention of cancer, there is no doubt that early studies have shown quite promising results in both preclinical and human/animal studies.

    However, there are still many challenges and limitations facing this field, including the lack of standardized protocols, the wide diversity of microbiota among people, and the many ethical and social considerations. Despite these challenges, the potential benefits of microbiota-based interventions for cancer prevention and treatment appear to be significant, and future research should focus on addressing these challenges and optimizing the use of microbiota-based interventions in clinical practice.

    Strategies for addressing ethical and social considerations include engaging with diverse communities and stakeholders, educating the general public about the existence of such interventions, ensuring access to all, having standardized regulations, and promoting transparency in the research and development processes.

  2. Discussion of the Potential Impact of Incorporating Microbiota-Based Interventions In Cancer Prevention And Treatment

    Incorporating microbiota-based interventions in cancer prevention and treatment has the potential to significantly impact cancer outcomes. By targeting the human microbiota, these treatment could potentially improve the efficiency of existing cancer treatments, while also reducing treatment-related side effects, and improving overall survival rates. Microbiota-based interventions also have the potential to prevent the development of certain cancers by reducing inflammation and enhancing immune function.

  3. Final Thoughts On The Role Of Microbiota In Cancer

    Microbiota can play a major role in maintaining human health and well-being. The emerging evidence linking the role of microbiota in cancer is a major indication of the hidden potential for developing new microbiota-based interventions for cancer prevention and treatment. These interventions have a significant potential to be effective, safe, and well-tolerated since they are being taken from the patient’s own microbiome itself. However, ethical and social considerations also must be taken into account to ensure that access to these interventions is available for all and that their use does not create new health disparities.

    From where we stand today, a lot of research is still needed to fully understand the complex relationship that exists between the human microbiota and cancer, and to develop effective and targeted microbiota-based interventions.


  1. Jandhyala, S.M., Talukdar, R., Subramanyam, C., Vuyyuru, H., Sasikala, M. and Reddy, D.N., 2015. Role of the normal gut microbiota. World journal of gastroenterology: WJG, 21(29), p.8787.
  2. Thursby, E. and Juge, N., 2017. Introduction to the human gut microbiota. Biochemical journal, 474(11), pp.1823-1836.
  3. Thursby, E. and Juge, N., 2017. Introduction to the human gut microbiota. Biochemical journal, 474(11), pp.1823-1836.
  4. Korecka, A. and Arulampalam, V., 2012. The gut microbiome: scourge, sentinel or spectator?. Journal of oral microbiology, 4(1), p.9367.
  5. Lloyd-Price, J., Abu-Ali, G. and Huttenhower, C., 2016. The healthy human microbiome. Genome medicine, 8(1), pp.1-11.
  6. Bull, M.J. and Plummer, N.T. (2014) Part 1: The human gut microbiome in health and disease, Integrative medicine (Encinitas, Calif.). U.S. National Library of Medicine. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4566439/
  7. Vivarelli, S., Salemi, R., Candido, S., Falzone, L., Santagati, M., Stefani, S., Torino, F., Banna, G.L., Tonini, G. and Libra, M., 2019. Gut microbiota and cancer: from pathogenesis to therapy. Cancers, 11(1), p.38.
  8. Guo, Y., Zhang, Y., Gerhard, M., Gao, J.J., Mejias-Luque, R., Zhang, L., Vieth, M., Ma, J.L., Bajbouj, M., Suchanek, S. and Liu, W.D., 2020. Effect of Helicobacter pylori on gastrointestinal microbiota: a population-based study in Linqu, a high-risk area of gastric cancer. Gut, 69(9), pp.1598-1607.
  9. Gao, J.J., Zhang, Y., Gerhard, M., Mejias-Luque, R., Zhang, L., Vieth, M., Ma, J.L., Bajbouj, M., Suchanek, S., Liu, W.D. and Ulm, K., 2018. Association between gut microbiota and Helicobacter pylori-related gastric lesions in a high-risk population of gastric cancer. Frontiers in cellular and infection microbiology, 8, p.202.
  10. Patyar, S., Joshi, R., Byrav, D.S., Prakash, A., Medhi, B. and Das, B.K., 2010. Bacteria in cancer therapy: a novel experimental strategy. Journal of biomedical science, 17(1), pp.1-9.
  11. Felgner, S., Kocijancic, D., Frahm, M. and Weiss, S., 2016. Bacteria in cancer therapy: renaissance of an old concept. International journal of microbiology, 2016.
  12. Sarotra, P. and Medhi, B., 2016. Use of bacteria in cancer therapy. Current Strategies in Cancer Gene Therapy, pp.111-121.
  13. Moysidou, C.M. and Owens, R.M., 2021. Advances in modelling the human microbiome–gut–brain axis in vitro. Biochemical Society Transactions, 49(1), pp.187-201.
  14. Chen, X., D’Souza, R. and Hong, S.T., 2013. The role of gut microbiota in the gut-brain axis: current challenges and perspectives. Protein & cell, 4, pp.403-414.
  15. Coker, O.O., Liu, C., Wu, W.K.K., Wong, S.H., Jia, W., Sung, J.J. and Yu, J., 2022. Altered gut metabolites and microbiota interactions are implicated in colorectal carcinogenesis and can be non-invasive diagnostic biomarkers. Microbiome, 10(1), p.35.
  16. Li, J., Zhang, A.H., Wu, F.F. and Wang, X.J., 2022. Alterations in the gut microbiota and their metabolites in colorectal cancer: recent progress and future prospects. Frontiers in Oncology, 12, p.841552.
  17. Yazici, C., Wolf, P.G., Kim, H., Cross, T.W.L., Vermillion, K., Carroll, T., Augustus, G.J., Mutlu, E., Tussing-Humphreys, L., Braunschweig, C. and Xicola, R.M., 2017. Race-dependent association of sulfidogenic bacteria with colorectal cancer. Gut, 66(11), pp.1983-1994.
  18. Al Bander, Z., Nitert, M.D., Mousa, A. and Naderpoor, N., 2020. The gut microbiota and inflammation: an overview. International journal of environmental research and public health, 17(20), p.7618.
  19. Mukherjee, S., Joardar, N., Sengupta, S. and Babu, S.P.S., 2018. Gut microbes as future therapeutics in treating inflammatory and infectious diseases: lessons from recent findings. The Journal of nutritional biochemistry, 61, pp.111-128.
  20. Ferreira, C.M., Vieira, A.T., Vinolo, M.A.R., Oliveira, F.A., Curi, R. and Martins, F.D.S., 2014. The central role of the gut microbiota in chronic inflammatory diseases. Journal of immunology research, 2014.
  21. Rutsch, A., Kantsjö, J.B. and Ronchi, F., 2020. The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology. Frontiers in immunology, 11, p.604179.
  22. Zhou, C.B., Zhou, Y.L. and Fang, J.Y., 2021. Gut microbiota in cancer immune response and immunotherapy. Trends in cancer, 7(7), pp.647-660.
  23. Cheng, W.Y., Wu, C.Y. and Yu, J., 2020. The role of gut microbiota in cancer treatment: friend or foe?. Gut, 69(10), pp.1867-1876.
  24. Kim, D., Zeng, M.Y. and Núñez, G., 2017. The interplay between host immune cells and gut microbiota in chronic inflammatory diseases. Experimental & molecular medicine, 49(5), pp.e339-e339.
  25. Park, C.H., Eun, C.S. and Han, D.S., 2018. Intestinal microbiota, chronic inflammation, and colorectal cancer. Intestinal research, 16(3), p.338.
  26. Bollrath, J. and Powrie, F.M., 2013, November. Controlling the frontier: regulatory T-cells and intestinal homeostasis. In Seminars in immunology (Vol. 25, No. 5, pp. 352-357). Academic Press.
  27. Louis, P., Hold, G.L. and Flint, H.J., 2014. The gut microbiota, bacterial metabolites and colorectal cancer. Nature reviews microbiology, 12(10), pp.661-672.
  28. Rooks, M.G. and Garrett, W.S., 2016. Gut microbiota, metabolites and host immunity. Nature reviews immunology, 16(6), pp.341-352.
  29. Meng, C., Bai, C., Brown, T.D., Hood, L.E. and Tian, Q., 2018. Human gut microbiota and gastrointestinal cancer. Genomics, proteomics & bioinformatics, 16(1), pp.33-49.
  30. Ren, Z., Li, A., Jiang, J., Zhou, L., Yu, Z., Lu, H., Xie, H., Chen, X., Shao, L., Zhang, R. and Xu, S., 2019. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut, 68(6), pp.1014-1023.
  31. Cancer.net (no date) Cancer.Net. Available at: https://www.cancer.net/ (Accessed: April 15, 2023).
  32. What is a bone marrow transplant (stem cell transplant)? (2021) Cancer.Net. Available at: https://www.cancer.net/navigating-cancer-care/how-cancer-treated/bone-marrowstem-cell-transplantation/what-bone-marrow-transplant-stem-cell-transplant (Accessed: April 15, 2023).
  33. Schwabe, R.F. and Jobin, C., 2013. The microbiome and cancer. Nature Reviews Cancer, 13(11), pp.800-812.
  34. Geller, L.T., Barzily-Rokni, M., Danino, T., Jonas, O.H., Shental, N., Nejman, D., Gavert, N., Zwang, Y., Cooper, Z.A., Shee, K. and Thaiss, C.A., 2017. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science, 357(6356), pp.1156-1160.
  35. Kostic, A.D., Gevers, D., Pedamallu, C.S., Michaud, M., Duke, F., Earl, A.M., Ojesina, A.I., Jung, J., Bass, A.J., Tabernero, J. and Baselga, J., 2012. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome research, 22(2), pp.292-298.
  36. Wang, T., Cai, G., Qiu, Y., Fei, N., Zhang, M., Pang, X., Jia, W., Cai, S. and Zhao, L., 2012. Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. The ISME journal, 6(2), pp.320-329.
  37. Pushalkar, S., Hundeyin, M., Daley, D., Zambirinis, C.P., Kurz, E., Mishra, A., Mohan, N., Aykut, B., Usyk, M., Torres, L.E. and Werba, G., 2018. The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune SuppressionMicrobiome Influences Pancreatic Oncogenesis. Cancer discovery, 8(4), pp.403-416.
  38. Lee, S.H., Sung, J.Y., Yong, D., Chun, J., Kim, S.Y., Song, J.H., Chung, K.S., Kim, E.Y., Jung, J.Y., Kang, Y.A. and Kim, Y.S., 2016. Characterization of microbiome in bronchoalveolar lavage fluid of patients with lung cancer comparing with benign mass like lesions. Lung cancer, 102, pp.89-95.
  39. Ajab, S., Zoughbor, S., Labania, L., Olanda, M., Östlundh, L. and Al Rasbi, Z., 2022. The role of microbiota in immunotherapy outcomes in colorectal cancer patients: A protocol for a systematic review. Plos one, 17(8), p.e0273314.
  40. Lin, Y., Kong, D.X. and Zhang, Y.N., 2022. Does the microbiota composition influence the efficacy of colorectal cancer immunotherapy?. Frontiers in Oncology, p.1257.
  41. Najmi, M., Tran, T., Witt, R.G. and Nelson, K.C., 2022. Modulation of the Gut Microbiome to Enhance Immunotherapy Response in Metastatic Melanoma Patients: A Clinical Review. Dermatology and Therapy, 12(11), pp.2489-2497.
  42. Bacteroidales (no date) Bacteroidales – an overview | ScienceDirect Topics. Available at: https://www.sciencedirect.com/topics/medicine-and-dentistry/bacteroidales (Accessed: April 15, 2023).
  43. Ajab, S., Zoughbor, S., Labania, L., Olanda, M., Östlundh, L. and Al Rasbi, Z., 2022. The role of microbiota in immunotherapy outcomes in colorectal cancer patients: A protocol for a systematic review. Plos one, 17(8), p.e0273314.
  44. Cheng, W.Y., Wu, C.Y. and Yu, J., 2020. The role of gut microbiota in cancer treatment: friend or foe?. Gut, 69(10), pp.1867-1876.
  45. Jain, T., Sharma, P., Are, A.C., Vickers, S.M. and Dudeja, V., 2021. New insights into the cancer–microbiome–immune axis: decrypting a decade of discoveries. Front Immunol 12: 622064.
  46. Heshiki, Y., Vazquez-Uribe, R., Li, J., Ni, Y., Quainoo, S., Imamovic, L., Li, J., Sørensen, M., Chow, B.K., Weiss, G.J. and Xu, A., 2020. Predictable modulation of cancer treatment outcomes by the gut microbiota. Microbiome, 8, pp.1-14.
  47. Ma, J., Zhu, W. and Liu, B., 2021. Role of gut microbiome in the outcome of cancer immunotherapy. International Journal of Cancer, 149(4), pp.760-768.
  48. Abdollahi-Roodsaz, S., Abramson, S.B. and Scher, J.U., 2016. The metabolic role of the gut microbiota in health and rheumatic disease: mechanisms and interventions. Nature Reviews Rheumatology, 12(8), pp.446-455.
  49. Kumar, M., Babaei, P., Ji, B. and Nielsen, J., 2016. Human gut microbiota and healthy aging: recent developments and future prospective. Nutrition and Healthy aging, 4(1), pp.3-16.
  50. Deleemans, J.M., Chleilat, F., Reimer, R.A., Henning, J.W., Baydoun, M., Piedalue, K.A., McLennan, A. and Carlson, L.E., 2019. The chemo-gut study: Investigating the long-term effects of chemotherapy on gut microbiota, metabolic, immune, psychological and cognitive parameters in young adult Cancer survivors; study protocol. BMC cancer, 19(1), pp.1-11.
  51. Alexander, J.L., Wilson, I.D., Teare, J., Marchesi, J.R., Nicholson, J.K. and Kinross, J.M., 2017. Gut microbiota modulation of chemotherapy efficacy and toxicity. Nature Reviews Gastroenterology & Hepatology, 14(6), pp.356-365.
  52. Karin, M., Jobin, C. and Balkwill, F., 2014. Chemotherapy, immunity and microbiota–a new triumvirate. Nat Med, 20(2), pp.126-127.
  53. Souza, R.O., Miranda, V.C., Quintanilha, M.F., Gallotti, B., Oliveira, S.R., Silva, J.L., Alvarez-Leite, J.I., Jesus, L.C., Azevedo, V., Vital, K.D. and Fernandes, S.O., 2023. Evaluation of the Treatment with Akkermansia muciniphila BAA-835 of Chemotherapy-induced Mucositis in Mice. Probiotics and Antimicrobial Proteins, pp.1-18.
  54. Wang, G., Si, Q., Yang, S., Jiao, T., Zhu, H., Tian, P., Wang, L., Li, X., Gong, L., Zhao, J. and Zhang, H., 2020. Lactic acid bacteria reduce diabetes symptoms in mice by alleviating gut microbiota dysbiosis and inflammation in different manners. Food & function, 11(7), pp.5898-5914.
  55. Riglar, D.T. and Silver, P.A., 2018. Engineering bacteria for diagnostic and therapeutic applications. Nature Reviews Microbiology, 16(4), pp.214-225.
  56. Zheng, D.W., Li, R.Q., An, J.X., Xie, T.Q., Han, Z.Y., Xu, R., Fang, Y. and Zhang, X.Z., 2020. Prebiotics‐encapsulated probiotic spores regulate gut microbiota and suppress colon cancer. Advanced Materials, 32(45), p.2004529.
  57. Fotiadis, C.I., Stoidis, C.N., Spyropoulos, B.G. and Zografos, E.D., 2008. Role of probiotics, prebiotics and synbiotics in chemoprevention for colorectal cancer. World journal of gastroenterology: WJG, 14(42), p.6453.
  58. Papanicolas, L.E., Gordon, D.L., Wesselingh, S.L. and Rogers, G.B., 2018. Not just antibiotics: is cancer chemotherapy driving antimicrobial resistance?. Trends in microbiology, 26(5), pp.393-400.
  59. Pandya, G., Kirtonia, A., Singh, A., Goel, A., Mohan, C.D., Rangappa, K.S., Pandey, A.K., Kapoor, S., Tandon, S., Sethi, G. and Garg, M., 2022, November. A comprehensive review of the multifaceted role of the microbiota in human pancreatic carcinoma. In Seminars in cancer biology (Vol. 86, pp. 682-692). Academic Press.
  60. Anfossi, S. and Calin, G.A., 2020. Gut microbiota: A new player in regulating immune-and chemo-therapy efficacy. Cancer Drug Resistance, 3(3), p.356.
  61. Routy, B., Le Chatelier, E., Derosa, L., Duong, C.P., Alou, M.T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M.P. and Fidelle, M., 2018. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors. Science, 359(6371), pp.91-97.
  62. Europe, P.M.C., 2015. free article][Abstract][Google Scholar] Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW. Man Lei Y, Jabri B, Alegre ML, Chang EB, Gajewski TF, Science (New York, NY), 350, p.1084.
  63. Gopalakrishnan, V., Spencer, C.N., Nezi, L., Reuben, A., Andrews, M.C., Karpinets, T.V., Prieto, P.A., Vicente, D., Hoffman, K., Wei, S.C. and Cogdill, A.P., 2018. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients. Science, 359(6371), pp.97-103.
  64. Sun, J., Liu, S., Ling, Z., Wang, F., Ling, Y., Gong, T., Fang, N., Ye, S., Si, J. and Liu, J., 2019. Fructooligosaccharides ameliorating cognitive deficits and neurodegeneration in APP/PS1 transgenic mice through modulating gut microbiota. Journal of agricultural and food chemistry, 67(10), pp.3006-3017.
  65. Rafter, J., 2003. Probiotics and colon cancer. Best Practice & Research Clinical Gastroenterology, 17(5), pp.849-859.
  66. Wang, H., Lee, I.S., Braun, C. and Enck, P., 2016. Effect of probiotics on central nervous system functions in animals and humans: a systematic review. Journal of neurogastroenterology and motility, 22(4), p.589.
  67. Wang, L., He, X., Ugai, T., Haruki, K., Lo, C.H., Hang, D., Akimoto, N., Fujiyoshi, K., Wang, M., Fuchs, C.S. and Meyerhardt, J.A., 2021. Risk factors and incidence of colorectal cancer according to major molecular subtypes. JNCI Cancer Spectrum, 5(1), p.pkaa089.
  68. Gupta, N., Jangid, A.K., Pooja, D. and Kulhari, H., 2019. Inulin: A novel and stretchy polysaccharide tool for biomedical and nutritional applications. International journal of biological macromolecules, 132, pp.852-863.
  69. Pool-Zobel, B.L., 2005. Inulin-type fructans and reduction in colon cancer risk: review of experimental and human data. British Journal of Nutrition, 93(S1), pp.S73-S90.
  70. Bornet, F.R. and Brouns, F., 2002. Immune-stimulating and gut health-promoting properties of short-chain fructo-oligosaccharides. Nutrition reviews, 60(10), pp.326-334.
  71. Macfarlane, G.T., Steed, H. and Macfarlane, S., 2008. Bacterial metabolism and health‐related effects of galacto‐oligosaccharides and other prebiotics. Journal of applied microbiology, 104(2), pp.305-344.
  72. Maio, G.D., Monda, V.I.N.C.E.N.Z.O., Messina, A., Polito, R., Monda, M., Tartaglia, N.I.C.O.L.A., Ambrosio, A., Pisanelli, D.A.N.I.E.L.A., Asmundo, A.L.E.S.S.I.O., Nunno, N.D. and Ametta, A., 2020. Physical activity and modification of lifestyle induce benefits on the health status. Acta Medica Mediterranea, 36(3), pp.1913-1919.
  73. Deepak, V., Ramachandran, S., Balahmar, R.M., Pandian, S.R.K., Sivasubramaniam, S.D., Nellaiah, H. and Sundar, K., 2016. In vitro evaluation of anticancer properties of exopolysaccharides from Lactobacillus acidophilus in colon cancer cell lines. In Vitro Cellular & Developmental Biology-Animal, 52, pp.163-173.
  74. Reghu, S. and Miyako, E., 2022. Nanoengineered bifidobacterium bifidum with optical activity for photothermal cancer immunotheranostics. Nano Letters, 22(5), pp.1880-1888.
  75. Pakbin, B., Dibazar, S.P., Allahyari, S., Javadi, M., Amani, Z., Farasat, A. and Darzi, S., 2022. Anticancer properties of probiotic Saccharomyces boulardii supernatant on human breast cancer cells. Probiotics and Antimicrobial Proteins, pp.1-9.
  76. Dong, L., Xie, J., Wang, Y. and Zuo, D., 2020. Gut microbiota and immune responses. Gut Microbiota and Pathogenesis of Organ Injury, pp.165-193.
  77. Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D.P., Pfirschke, C., Engblom, C., Pittet, M.J. and Schlitzer, A., 2013. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. science, 342(6161), pp.971-976.
  78. Garrett, W.S., 2015. Cancer and the microbiota. Science, 348(6230), pp.80-86.
  79. Zitvogel, L., Ma, Y., Raoult, D., Kroemer, G. and Gajewski, T.F., 2018. The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies. Science, 359(6382), pp.1366-1370.
Team PainAssist
Team PainAssist
Written, Edited or Reviewed By: Team PainAssist, Pain Assist Inc. This article does not provide medical advice. See disclaimer
Last Modified On:April 19, 2023

Recent Posts

Related Posts